Post-herpetic Neuralgia Clinical Trial
Official title:
A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia
This study was designed to characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN).
This was an interventional, randomized, parallel, placebo-controlled, dose ranging, double-blind treatment study consisting of 3 periods i.e. Screening, Treatment, and Treatment withdrawal. The study was planned in two cohorts. The initial cohort had three treatment arms i.e. Placebo b.i.d., EMA401 25 mg b.i.d., or EMA401 100 mg b.i.d. Following an unblinded safety review by an independent DMC, the second cohort was to have been initiated with an additional treatment arm i.e. EMA401 300 mg b.i.d.. Due to the premature study termination, the second cohort was not initiated. At the end of treatment period the 25mg BID and 100mg BID arms were re-randomized (1:1) to the same treatment or placebo. Placebo arm stayed on placebo. The planned duration of treatment period was 12 weeks and 1 week of treatment withdrawal at the end of treatment period. The study was terminated early due to pre-clinical toxicity data that became available after start of trial. Novartis implemented a Urgent Safety Measure (USM) which instructed sites to discontinue study treatment immediately and to have all patients return for additional laboratory assessments (full hematology including coagulation and clinical chemistry panel). Safety data from the USM was presented as a separate outcome measure table and not included in the Adverse Event section. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01944150 -
Association of Transcutaneous Electrical Nerve Stimulation and Hypnosis
|
N/A | |
Completed |
NCT00159666 -
Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia
|
Phase 4 | |
Completed |
NCT00305357 -
Evolution of Pain From Herpes Zoster
|
||
Not yet recruiting |
NCT03120962 -
Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia
|
N/A | |
Completed |
NCT02701374 -
Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia
|
Phase 2 | |
Completed |
NCT02318719 -
DS-5565 Phase III Study for Post-herpetic Neuralgia
|
N/A | |
Completed |
NCT01752699 -
Methadone in Post-Herpetic Neuralgia Pain
|
Phase 3 | |
Completed |
NCT01250561 -
Reduction of Postherpetic Neuralgia in Herpes Zoster
|
N/A | |
Completed |
NCT02607280 -
DS-5565 Phase III Study for Renal Impairment in Japanese Subjects
|
Phase 3 | |
Completed |
NCT01037088 -
Effects of Vaporized Marijuana on Neuropathic Pain
|
Phase 1/Phase 2 | |
Completed |
NCT02633306 -
Transcranial Magnetic Stimulation for Facial Pain
|
N/A | |
Recruiting |
NCT05593237 -
Transcranial Magnetic Stimulation for Chronic Neuropathic Pain
|
N/A | |
Completed |
NCT01848730 -
Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia
|
Phase 2 |